Department of Medical Oncology, Shulan (Hangzhou) Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou, Zhejiang, China.
Cancer Center, Qilu Hospital of Shandong University, Jinan, Shandong, China.
J Gastroenterol Hepatol. 2021 Sep;36(9):2601-2609. doi: 10.1111/jgh.15475. Epub 2021 Mar 10.
Programmed cell death-ligand 1 (PD-L1) immunohistochemistry score has been approved as the predictive biomarker for anti-PD1/PD-L1 therapy in several advanced malignancies. Although its predictive role remained inconclusive in hepatocellular carcinoma, ongoing study of anti-PD1/PD-L1 therapy showed promising results. However, less is known about the PD-L1 immunohistochemistry score and factors correlated with it in hepatocellular carcinoma. We investigated PD-L1 immunohistochemistry scores in a large cohort of hepatocellular carcinoma, as well as its correlation with various clinical and genomic factors.
Immunohistochemistry was performed to detect the expression of PD-L1 protein in 315 hepatocellular carcinoma tissues. All slides were independently reviewed by three senior pathologists. Next-generation YS panel (450 genes) sequencing was performed on 309 patients.
Higher PD-L1 expression as measured by combined positive score (CPS) was associated with increased Edmondson-Steiner grade (grade III vs II, P = 0.041) and TP53 mutations (P = 0.021). PD-L1 CPS had no correlation with tumor mutational burden (Spearman's correlation coefficient 0.067). PD-L1 CPS was not significantly associated with hepatitis B virus infection.
Our data indicated that patients with higher Edmondson-Steiner grade (grade III) had significantly higher PD-L1 CPS than patients with lower Edmondson-Steiner grade (grade II). Patients with TP53 mutations had significantly higher PD-L1 expression.
程序性死亡配体 1（PD-L1）免疫组织化学评分已被批准为几种晚期恶性肿瘤抗 PD-1/PD-L1 治疗的预测生物标志物。尽管其在肝细胞癌中的预测作用仍不确定，但抗 PD-1/PD-L1 治疗的持续研究显示出有希望的结果。然而，关于肝细胞癌中 PD-L1 免疫组织化学评分及其与各种临床和基因组因素的相关性知之甚少。我们调查了大量肝细胞癌中 PD-L1 免疫组织化学评分及其与各种临床和基因组因素的相关性。
对 315 例肝细胞癌组织进行 PD-L1 蛋白表达的免疫组织化学检测。所有切片均由三位资深病理学家独立复查。对 309 例患者进行了下一代 YS 面板（450 个基因）测序。
用联合阳性评分（CPS）衡量的 PD-L1 表达越高，与 Edmondson-Steiner 分级（III 级与 II 级，P=0.041）和 TP53 突变（P=0.021）增加有关。PD-L1 CPS 与肿瘤突变负担无相关性（Spearman 相关系数 0.067）。PD-L1 CPS 与乙型肝炎病毒感染无显著相关性。
我们的数据表明，Edmondson-Steiner 分级较高（III 级）的患者 PD-L1 CPS 明显高于分级较低（II 级）的患者。TP53 突变患者的 PD-L1 表达明显更高。
